source
- AstraZeneca and Amgen’s Tezspire eyes Dupixent’s EoE stronghold after late-stage trial winAnalysts note that AstraZeneca and Amgen have secured a late‑stage trial win for Tezspire, positioning the drug as a possible challenger to Dupixent in eosinophilic esophagitis (EoE). Dupixent re…
- Biotech Index Surges as IPOs and M&A Activity Accelerate in 2026The XBI biotech index, which had fallen to about $64 per share three years ago, has climbed back to near $170, almost doubling its value over the past year. Investor interest is reflected in a wav…